RxDoctor Payments Data

Frankie Cate

Acute Care · Knoxville, TNNPI 1619479789

Payments from drug & device makers

$4,229in general payments, 2019–2025

Across 189 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$682
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$674
  • Novartis$412
  • E.r. Squibb & Sons, L.L.C.$261
  • Johnson & Johnson$228
  • Kiniksa Pharmaceuticals International, PLC$220
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,229100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,229 in reported general payments places this provider in the 90th percentile of 738 acute care providers in Tennessee.

See all acute care providers in Tennessee

Medicare billing

Part B allowed, 2024
$42,160
Medicare patients
311
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban388$448,725
JardianceEmpagliflozin124$108,979
XareltoRivaroxaban90$91,827
EntrestoSacubitril/Valsartan65$69,667
BrilintaTicagrelor87$56,219
Repatha SureclickEvolocumab42$44,227
Prasugrel Hcl69$6,118
Ranolazine ErRanolazine39$4,118
Metoprolol Succinate263$3,564
Atorvastatin Calcium329$3,308
Valsartan61$3,070
Rosuvastatin Calcium162$2,405
Ezetimibe72$1,838
Amiodarone Hcl66$1,558
ClopidogrelClopidogrel Bisulfate144$1,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$448,725388 claims
Boehringer IngelheimJardiance$86$108,979124 claims
Johnson & JohnsonXarelto$228$91,82790 claims
NovartisEntresto$412$69,66765 claims
AstraZenecaBrilinta$53$56,21987 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 738 acute care providers in Tennessee.

Other acute care in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →